Founders
Dr. David Ben-Gershon
David combines deep expertise in experimental entomology with a lifelong passion for invention and innovation. Holding a Ph.D. in biology from the Russian Academy of Sciences, David's diverse career includes groundbreaking research in insect physiology and evolutionary biology. At CalliFarma, David spearheads the development of cutting-edge maggot therapy solutions, extending treatment effectiveness and accessibility through continuous innovations. His work embodies a synergy of scientific discovery and practical technological implementation, placing CalliFarma at the forefront of biotherapy and medical entomology.
Dr. Nehama Milson-Ben-Gershon
Nehama is a seasoned rehabilitation physician and wound care specialist with over 20 years of clinical experience. Trained at Ryazan Medical School (Russia) with additional expertise in neurology and pediatrics, she has worked at Beit Levinstein, Soroka, and Hadassah Medical Centers, and as a unit physician in the IDF. At CalliFarma, Nehama shapes the medical strategy for maggot therapy, collaborating with co-founder Dr. David Ben-Gershon to develop patent-pending, ISO-certified biotherapy technologies. A passionate educator, she creates practical training programs for healthcare professionals, enhancing adoption of wound care solutions. Her advanced certifications in ultrasound-guided injections, chronic pain management, and wound care education underscore her commitment to innovative, patient-centered care.
✉️ dr_nehama@callifarma.com
📞 050-925-4452 (Hebrew)
Consultants & Advisors
Mr. Leonid Margulis
Leonid Margulis, Ph.D., is a pharmaceutical expert with over 25 years of experience in pre-formulation, formulation, and analytical product development, serving as CalliFarma’s Consultant on Pharmaceutical Development and Innovation. Holding a Ph.D. in Physical Chemistry from the Institute of Chemical Physics (USSR Academy of Sciences) and post-doctoral training from New York University, Leonid has led groundbreaking work at Pfizer, Par Pharmaceutical, and VYNE Therapeutics. His expertise spans liquid and semi-solid formulations, non-conventional dosage forms like implants and topical sprays, and novel drug delivery technologies. At CalliFarma, Leonid guides the optimization of maggot therapy products, from pre-clinical development to market readiness, leveraging his skills in cross-functional team leadership and external collaborations to enhance biotherapy innovation.
Mr. Larry Loev
Larry Loev brings over 15 years of leadership in university technology commercialization to his role as Consultant at CalliFarma. With a background in physics and a distinguished career spanning research engineering, technical product management, and R&D leadership, Larry currently serves as CEO of the University IP Commercialization Office at Ariel University. His expertise in licensing and start-up formation has bridged cutting-edge innovations—spanning medical devices, biotech, and agro-technologies—to market success. At CalliFarma, Larry drives the strategic transfer and commercialization of maggot therapy technologies, leveraging his skills to secure partnerships, optimize licensing terms, and accelerate market entry. His proven ability to connect researchers, entrepreneurs, and investors ensures CalliFarma’s biotherapy solutions reach their full commercial potential.
🔗 LinkedIn
✉️ hanasdaddy@gmail.com
📞 +972-52-8749020
Dr. Ronald Sherman, M.D., M.Sc., DTM&H
Dr. Ronald Sherman is a globally recognized pioneer in biotherapy, renowned for his groundbreaking work in reintroducing maggot therapy to modern medical practice. With expertise in infectious diseases, medical entomology, and parasitology, he co-founded Monarch Labs, where he spearheaded the development and distribution of medicinal maggots (Medical Maggots™), achieving FDA approval as the first live animal medical device. As Executive Director of the BioTherapeutics, Education, and Research (BTER) Foundation since 2003, Dr. Sherman has advanced patient care, education, and research in biotherapy. At CalliFarma, he serves as a pivotal consultant and adviser, guiding the refinement of maggot therapy solutions with his unparalleled experience in healthcare delivery, regulatory compliance, and business development. His visionary leadership strengthens CalliFarma’s position as an innovator in wound care.
Mr. Zee Schwab
Zee Schwab is a seasoned venture capital expert and startup strategist. As a Partner at Actuate Ventures and Techstars ’23 alum, Zee brings extensive experience in healthtech and infotech, having co-founded Sayar Care (clinically tested formulas) and Column Inc (decentralized intelligence network). With a background in biochemistry and pediatric oncology support at Memorial Sloan Kettering Cancer Center, Zee has guided startups worldwide—advising on product-market fit, go-to-market strategies, and fundraising as a Strategic Advisor at ZiL. At CalliFarma, Zee drives growth by refining business strategies, securing investor partnerships, and accelerating the commercialization of maggot therapy solutions, ensuring scalability and market impact.